Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages

  Geng, Elvin H ^a,b   Bwana, Mwebesa B ^b,c   Muyindike, Winnie ^b,c   Glidden, David V ^a,b   Bangsberg, David R ^b,c,d   Neilands, Torsten B ^a   Bernheimer, Ingrid ^a   Musinguzi, Nicolas ^b,c   Yiannoutsos, Constantin T ^b,e   Martin, Jeffrey N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium   (United States)

^c MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

Africa; Antiretroviral therapy; Loss to follow up; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; EDUCATION; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALNUTRITION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RANDOM SAMPLE; RISK; SEX; THERAPY DELAY; TRAVEL; UGANDA; ADULT; CD4+ T LYMPHOCYTE; EDUCATIONAL STATUS; HEALTH CARE DELIVERY; MALE; MEDICATION COMPLIANCE; TREATMENT REFUSAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DELIVERY OF HEALTH CARE; EDUCATIONAL STATUS; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; MEDICATION ADHERENCE; TREATMENT REFUSAL; UGANDA;

MLCS; MLOWN;

EID: 84879740416     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828af5a6     Document Type: Article

References (32)

1. Nam SL, Fielding K, Avalos A, et al. The relationship of acceptance or denial of HIV-status to antiretroviral adherence among adult HIV patients in urban Botswana. Soc Sci Med. 2008;67:301-310.
2. Medley A, Garcia-Moreno C, McGill S, et al. Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes. Bull World Health Organ. 2004;82:299-307.
3. Siedner MJ, Lankowski A, Haberer JE, et al. Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS One. 2012;7:e39894.
4. Tuller DM, Bangsberg DR, Senkungu J, et al. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2009;14: 778-784.
5. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405-411.
6. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8: e1001056.
7. Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12:687-694.
8. Tayler-Smith K, Zachariah R, Massaquoi M, et al. Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Trans R Soc Trop Med Hyg. 2010;104:313-319.
9. Zachariah R, Harries AD, Manzi M, et al. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS One. 2006;1:e121.
10. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
11. Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51:135-139.
12. Micek MA, Gimbel-Sherr K, Baptista AJ, et al. Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr. 2009;52:397-405.
13. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300:506-507.
14. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541-554.
15. Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis. Br J Cancer. 2004;91:1229-1235.
16. Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Chichester, United Kingdom: John Wiley & Sons, Ltd; 1995.
17. Frangakis CE, Rubin DB. Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring. Biometrics. 2001;57:333-342.
18. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999; 8:3-15.
19. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7:147-177.
20. Zolopa A, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4:e5575.
21. Geng EH, Kreiswirth BN, Burzynski J, et al. Transmission trends for human immunodeficiency virus associated tuberculosis in New York City. Int J Tuberc Lung Dis. 2005;9:661-666.
22. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique. J Acquir Immune Defic Syndr. 2011;56:e39-e44.
23. Decroo T, Van Damme W, Kegels G, et al. Are expert patients an untapped resource for ART provision in sub-Saharan Africa? AIDS Res Treat. 2012;2012:749718.
24. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New Engl J Med. 2010;363: 1005-1015.
25. Van Rie A, Page-Shipp L, Scott L, et al. Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010;10:937-946.
26. Tsai AC, Bangsberg DR, Emenyonu N, et al. The social context of food insecurity among persons living with HIV/AIDS in rural Uganda. Soc Sci Med. 2011;73:1717-1724.
27. Miller CL, Bangsberg DR, Tuller DM, et al. Food insecurity and sexual risk in an HIV endemic community in Uganda. AIDSBehav. 2011;15:1512-1519.
28. Weiser SD, Young SL, Cohen CR, et al. Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr. 2011;94:1729S-1739S.
29. Tanser F, Barnighausen T, Cooke GS, et al. Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. Int J Epidemiol. 2009;38:1008-1016.
30. Tanser F, Lesueur D, Solarsh G, et al. HIV heterogeneity and proximity of homestead to roads in rural South Africa: an exploration using a geographical information system. Trop Med Int Health. 2000;5:40-46.
31. Geng EH, Glidden DV, Bangsberg DR, et al. A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol. 2012;175:1080-1087.
32. Yiannoutsos CT, An MW, Frangakis CE, et al. Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One. 2008;3:e3843.